Vertex Pharmaceuticals, Inc. (VRTX) Misses Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $463.85 +2.71%
EPS Growth %: +4.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +4.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $336 million versus the consensus estimate of $377.14 million.Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
- Micron Technology (MU) PT Raised to $1,550 at Needham
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
